Clinical Trial Update: A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating MRTX0902 in solid tumors with KRAS MAPK pathway mutations has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• MRTX0902

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Solid Tumor, Advanced Solid Tumor | Phase 1 | Status: TERMINATED